Volume | 3,517 |
|
|||||
News | - | ||||||
Day High | 4.7099 | Low High |
|||||
Day Low | 4.5001 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | APRE | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.62 | 4.5001 | 4.7099 | 4.5001 | 4.7028 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
153 | 3,517 | $ 4.58 | $ 16,092 | - | 2.78 - 8.8465 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:30:02 | 25 | $ 4.51 | USD |
Aprea Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.82M | 3.74M | - | 583k | -14.29M | -3.82 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aprea Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APRE Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.70 | 5.00 | 4.5001 | 4.73 | 6,744 | -0.1999 | -4.25% |
1 Month | 5.48 | 5.90 | 4.5001 | 5.15 | 9,825 | -0.9799 | -17.88% |
3 Months | 5.72 | 6.8799 | 4.5001 | 5.76 | 10,374 | -1.22 | -21.33% |
6 Months | 3.60 | 8.8465 | 3.50 | 6.20 | 22,628 | 0.9001 | 25.00% |
1 Year | 3.70 | 8.8465 | 2.78 | 4.77 | 25,653 | 0.8001 | 21.62% |
3 Years | 95.40 | 156.00 | 2.78 | 79.77 | 608,383 | -90.90 | -95.28% |
5 Years | 309.20 | 1,062.20 | 2.78 | 118.67 | 548,375 | -304.70 | -98.54% |
Aprea Therapeutics Description
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). |